DBVT - DBV Tech Projected Sales Volume

Official company branding of DBV Technologies (DBVT)

The investment potential of DBV Technologies S.A. (DBVT) is based on the anticipated FDA approval of pediatric allergy therapy and high market demand. The company's expected trading volumes visualize this trend, where 0.00 reflects the latest metric value. The business foundation consists of the Viaskin ecosystem with proprietary patches, while asset protection is ensured by patents, despite a temporary narrowing of the "economic moat" due to certification delays.

DBV Technologies - DBVT Company Projected Revenue (period 07/04/2022 - 11/13/2026)

Comprehensive metric breakdowns and analytics for DBV Technologies SA (DBVT)

- stock quotes and analyst forecast:
Stock Price DBV Technologies S.A.|DBVT - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization DBV Tech|DBVT - Total Company Value
- book capitalization information:
Accounting Value per Share DBV Technologies|DBVT - Company Book Value|Market Cap to Net Assets Ratio dbv-technologies.com|DBVT - Aggregate Asset Value
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio DBV Technologies S.A.|DBVT - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital DBV Technologies S.A.|DBVT - Company Cumulative Debt|Debts to Book Capitalization DBV Tech|DBVT - Company Long-Term Liabilities|Company Short-Term Debts DBV Technologies|Quick Liquidity dbv-technologies.com
- financial results and valuation multiples details:
DBVT - Company Profit|Expected Profit DBV Technologies S.A.|DBVT - Market Cap to Earnings|Future Price to Earnings DBV Technologies S.A.|DBVT - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DBV Tech|DBVT - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) DBV Technologies|DBVT - Net earnings per share for the trailing year|Quarterly EPS earnings growth dbv-technologies.com|DBVT - Expected net earnings per share growth this year|Earnings growth forecast for next year DBV Technologies S.A.
- issuer revenue and sales details:
DBVT - Company Total Revenue|Company Projected Revenue DBV Technologies S.A.|DBVT - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple DBV Tech
Analysis of all company metrics:DBV Technologies
Product sample of DBV Technologies SA

This indicator is calculated as a mathematical revenue projection that integrates current market trends and balance sheet operational dynamics to assess capitalization potential for DBV Technologies S.A. (DBVT). The metric reflects the probability of commercial success for the patch technology contingent upon FDA approval, allowing the company to evaluate financial risks associated with stringent regulatory requirements for the therapy through projected sales volumes.

Competitors of DBV Technologies S.A.

Projected Sales Volume KRYS|apogeetherapeutics.com - Company Revenue Forecast|Projected Sales Volume ARQT (Arcutis Biotherapeutics, Inc.)|Vericel Corp - Company Projected Revenue|ORKA: Company Future Sales Volume|SMTI: Company Projected Revenue|SLSN (solesence.com) - Company Future Sales Volume|Journey Medical Corporation - Company Future Revenue|Company Future Sales Volume FBRX|EMPG (Empro Group Inc.) - Company Projected Revenue Volume|Projected Sales Volume SLGL|AXIL - Company Expected Sales Volume|Projected Sales Volume MDCX (Medicus Pharma Ltd.)|VRCA - Company Future Sales Volume|Hoth - Projected Sales Volume|Company Future Revenue BFRI (Biofrontera Inc.)|vynetherapeutics.com (VYNE) - Company Projected Revenue|Company Revenue Forecast SNOA|Company Projected Revenue Quoin Pharmaceuticals Ltd|Company Expected Sales Volume azitrainc.com AZTR|Company Projected Revenue Dermata Therapeutics, Inc. (DRMA)|Company Projected Revenue ELAB (Elevai Labs Inc)|Company Projected Revenue Revance Therapeutics, Inc RVNC